4.91
-0.21 (-4.10%)
| Previous Close | 5.12 |
| Open | 5.10 |
| Volume | 3,277,130 |
| Avg. Volume (3M) | 1,271,904 |
| Market Cap | 280,110,688 |
| Price / Earnings (TTM) | 4.86 |
| Price / Earnings (Forward) | 526.32 |
| Price / Sales | 67.61 |
| Price / Book | 2.13 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2026 |
| Diluted EPS (TTM) | -0.630 |
| Total Debt/Equity (MRQ) | 57.92% |
| Current Ratio (MRQ) | 4.90 |
| Operating Cash Flow (TTM) | -59.88 M |
| Levered Free Cash Flow (TTM) | -39.71 M |
| Return on Assets (TTM) | -49.95% |
| Return on Equity (TTM) | -271.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Abeona Therapeutics Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.13 |
|
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.84% |
| % Held by Institutions | 63.35% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nan Fung Trinity (Hk) Ltd | 31 Dec 2025 | 956,770 |
| 52 Weeks Range | ||
| Median | 20.00 (307.33%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Mar 2026 | 20.00 (307.33%) | Buy | 5.14 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |